Congress Reauthorized SBIR/STTR Through 2031 — and Quietly Rewrote the Rules Every Deep-Tech Company Plays By
June 30, 2026 · 6 min read
Granted Research Team · Editorial policy
For six months at the start of 2026, the most important non-dilutive funding program for American deep-tech startups was technically dead. The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs — which together move roughly $4 billion a year from eleven federal agencies into small companies — had lapsed when their authorization expired and Congress failed to renew it on time. Agencies improvised, some opportunities froze, and founders who depend on the program spent the spring not knowing whether it would exist by summer.
That uncertainty ended on April 13, 2026, when President Trump signed the Small Business Innovation and Economic Security Act of 2026 (S. 3971), reauthorizing both programs through September 30, 2031. The relief was real. But the law did more than press "resume." It rewrote several of the rules that govern who can win, how much they can win, and how many times they can try — and those changes will outlast the news cycle that covered the reauthorization itself. This is the deep dive on what actually changed and how a company should adapt.
Why the lapse mattered — and why a five-year window is the real prize
It is easy to treat a reauthorization as a formality. It is not. Each prior extension of SBIR/STTR had been a short-leash affair, sometimes measured in months, which made long-range planning at agencies difficult and left founders unsure whether a Phase I award would have a Phase II to graduate into. A clean runway to 2031 is the single most valuable thing the new law delivers: it lets agencies design multi-year topic roadmaps, and it lets a founder rationally plan a Phase I → Phase II → commercialization arc that spans years rather than betting on a program that might vanish.
The lapse also created a practical wrinkle the law addresses directly: agencies that had unspent SBIR/STTR funds at the end of fiscal year 2026 are permitted to carry them into fiscal year 2027. For applicants, that means the funding pools heading into the next cycle may be larger than a normal year's appropriation would suggest — a tailwind worth knowing about when timing a submission.
The headline addition: $30 million "strategic breakthrough" awards
The most ambitious new provision is a Phase II vehicle called a strategic breakthrough award, with a ceiling as high as $30 million — an order of magnitude beyond a normal Phase II. It is deliberately narrow. The lane is available only at agencies whose annual required SBIR expenditures exceed $100 million, and the total spent on it is capped at 0.5% of an agency's overall extramural R&D budget. Agencies were required to brief Congress within 60 days of enactment on whether they even intend to use it.
The practical reading: this is a Department of War, NIH, NASA, and DOE story far more than an NSF or small-agency story. For founders in defense, biomedicine, space, and energy, it signals that the government wants a path to fund a small number of SBIR companies at a scale that can actually cross the "valley of death" into production — the chronic failure mode where a promising Phase II prototype never reaches a program of record or a real market. If your technology is genuinely strategic and your target agency is a big spender, the ceiling on what SBIR can do for you just rose dramatically. For everyone else, it is a useful signal of where federal ambition is pointed, not a lane you will compete in.
Per-company proposal caps: the end of the spray-and-pray era
Beginning in fiscal year 2027, agencies will be empowered to set their own caps on how many proposals a single company can submit — per solicitation, per topic, or per company. This is aimed squarely at a well-known pathology: a small number of "SBIR mills" that submit dozens or hundreds of proposals a year, win a high volume of awards, and sometimes never commercialize anything. The new screening tilts the program back toward companies that intend to build products.
For a founder, the strategic implication is straightforward. Volume is no longer a viable strategy. Each proposal slot is becoming a scarce resource, which raises the cost of a weak submission and the value of a strong one. The companies that thrive under caps are the ones that pick their topics carefully, do real customer discovery before writing, and submit fewer, better proposals. If your plan was to flood an agency with applications and see what sticks, that plan has an expiration date.
Mandatory national-security screening: the provision that will surprise founders
The most operationally consequential change for many applicants is the enhanced national-security screening. The law requires agencies to assess whether an applicant poses a national-security risk and to prohibit awards to small businesses with certain foreign ties or other identified security concerns. Agencies must strengthen their review processes across several dimensions: cybersecurity practices, patent and intellectual-property analysis, employee background checks, and risks tied to foreign countries of concern.
This is not boilerplate, and it is where otherwise-fundable companies can quietly lose. The companies most exposed are those with foreign investors on the cap table, co-founders or key personnel with ties to countries of concern, IP licensed from or developed with foreign institutions, or weak cybersecurity hygiene. The screening is also retrospective and ongoing in spirit — it is about the company's structure, not just a single form.
The defensive move is to get your house in order before you apply, not after you are invited. Map your ownership and affiliations. Understand who your investors are and where their capital originates. Document your cybersecurity posture. Clean up the provenance of your core IP. A company that can demonstrate a clean, well-documented structure has a real competitive advantage under the new regime; a company that treats the disclosures as an afterthought is exposing itself to a rejection that has nothing to do with the quality of its science.
The 90-day clock: a fix for the program's worst feature
The reauthorization also pushes agencies toward making award decisions within 90 days. Anyone who has been through the SBIR process knows why this matters: the program's chronic weakness has been time-to-money. A startup operating on a runway of months cannot easily wait the better part of a year between submission and a funded award. A tighter decision clock — if agencies hold to it — narrows the gap between "we applied" and "we can hire," which is the difference between SBIR being useful working capital and being a nice trophy that arrives too late to matter.
How agencies will translate this — and why timing matters
A crucial nuance: the Act sets the framework, but agencies implement it on their own timelines through their individual solicitations. That is why the first solicitations written under the new law — such as NSF's refreshed SBIR/STTR solicitation with its July 27, 2026 deadline — are worth reading closely. They are the first concrete evidence of how each agency is interpreting the proposal caps, the screening requirements, and the award structures. Expect divergence: the Department of War will emphasize the strategic-breakthrough and security provisions; civilian science agencies will emphasize commercialization and the proposal-cap mechanics. Read your target agency's specific solicitation as the operative document; read the Act as the explanation for why it says what it says.
What to do now
The reauthorization rewards companies that treat SBIR as a serious, multi-year strategy rather than a grant lottery:
- Plan to 2031. With a stable five-year window, build a real Phase I → Phase II → commercialization roadmap instead of one-off bets.
- Submit fewer, stronger proposals. Proposal caps are coming in FY2027; the spray-and-pray model is dead.
- Audit your national-security exposure now — ownership, foreign investors, key-personnel ties, IP provenance, and cybersecurity. This is where fundable companies lose.
- If you are in defense, biomed, space, or energy, watch the strategic-breakthrough lane — the $30M ceiling could change what SBIR can fund for you.
- Read your target agency's specific solicitation as the source of truth; the Act explains the why, the solicitation sets the rules.
Congress did not just keep the lights on. It changed what the building is for. The companies that read the new rules early will spend the next five years competing against a thinner, less-prepared field.